Enveric Archives - Green Market Report

StaffSeptember 20, 2023
daily-hit.jpg

5min00

The Daily Hit is a recap of the top financial news stories for Sept. 20, 2023.

On The Site

Cannabis Stocks Pop on News of SAFER Banking Act

Marijuana stocks shot up Wednesday after news broke that the SAFE Banking Act had been rewritten as the SAFER Banking Act, breathing new life into federal cannabis reform just weeks after the monumental news that the Biden administration recommended the rescheduling of marijuana. Read more here.

Mississippi Releases Revised Medical Cannabis Industry Rules

Mississippi cannabis regulators announced new revisions to industry regulations, with 202 pages of red-lined changes to the former rules released by the state Department of Health on Thursday.Read more here.

Kentucky Hemp Company Purchases Manufacturing Partner

Kentucky-based CBD maker Cornbread Hemp closed on the acquisition of an unnamed manufacturing partner, marking a transition to full vertical integration for the business. Read more here.

Leef Brands Closes Acquisition of Santa Barbara Cultivation Facility

California-based Leef Brands (CSE: LEEF) (OTC: LEEEF), formerly known as Icanic Brands, completed the acquisition of a 1,900-acre ranch in Santa Barbara County for $5.48 million, which the company intends to transform into “one of the largest biomass cultivation sites in California.” Read more here.

Enveric Receives Patent for Psilocybin Molecules

Enveric Biosciences (NASDAQ: ENVB) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders. Read more here.

Seelos Reports Mixed Results From Phase II Ketamine Study

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced top-line data demonstrating clinically meaningful treatment effects across multiple endpoints and a well-tolerated safety profile from the double-blind, placebo-controlled cohort (Part 2) of its Phase II study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in adults with Major Depressive Disorder (MDD). Read more here.

In Other News

Congress

Members of the U.S. House of Representatives, Oversight and Accountability Committee voted 30-14 today in favor of bipartisan legislation, H.R. 5040: The Cannabis Users’ Restoration of Eligibility (CURE) Act, which expands federal employment and advancement opportunities for those with a history of past cannabis use. Read more here.

Oklahoma

The Oklahoma Medical Marijuana Authority seized around 14,000 marijuana plants and 4,850 pounds of marijuana earlier this week. Not only did they seize thousands of pounds of illicit marijuana, but five businesses were also shut down as a result of the investigation. Read more here.

Nevada

On Tuesday, the Nevada Cannabis Compliance Board (CCB) approved a conditional license for a cannabis consumption lounge on the AREA15 campus, which houses popular attractions such as Meow Wolf’s Omega Mart, Illuminarium, and a recently announced Universal Halloween-themed park. Read more here.


Dave HodesApril 8, 2022
shutterstock_579231529-1-1280x853.jpg

7min00

While the numbers on the spreadsheets of psychedelics companies are still to be taken with a grain of salt, given that this is an emerging biotechnology industry still in the drug development stage, there are encouraging signs that perhaps 2022 could be the beginning of a rebound.

Some of the financial downbeat news from 2021 is more than offset by acquisitions and partnerships news that have or will soon give the psychedelics industry the sort of financial firepower that has been predicted for years. For example, the January acquisition of Eleusis, a clinical-stage life science company, by Silver Spike Acquisition Corporation, created a combined company enterprise value of approximately $446 million.

Here are the results of financial reports from the fiscal year 2021 for three selected psychedelics companies, each with a note about what the company has done or is doing to advance its standing and give it some real financial muscle going forward.

Enveric Biosciences Inc. (NASDAQ: ENVB), is a neuroscience company developing next-generation psychedelic-inspired mental health medicines, based in Naples, Florida.

Enveric made a couple of strategic moves in 2021 to build on its foundational aspirations, including being added to the new AdvisorShare Psychedelics ETF trading on the NYSE Arca exchange; and filing and publishing four patent applications for psychedelic-inspired drug candidates with the World Intellectual Property Organization (WIPO). The four patent applications are focused on the tryptamine family of novel molecules. The company’s net loss for the year was $48.8 million, $40 million more than in 2020, but it reported it still had $17.4 million in cash with working capital of $15.3 million and had raised $10 million during the year that it expects to use to advance its new drug delivery platform and assist with managing its growing IP portfolio. 

Good news for 2022: The company also announced a collaboration with the University of Calgary on a clinical trial for cancer-related distress, expected to launch in 2023. And in September, Enveric completed the acquisition of MagicMed Industries Inc., a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N, N-dimethyltryptamine (DMT), and other molecular derivatives with applications across multiple indications, in an all-stock transaction. With this acquisition, Enveric intends to expand into a next-generation neuroscience drug discovery platform of novel psychedelics that addresses the large unmet mental health challenges related to the central nervous system.

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS), is a clinical-stage natural psychedelic drug development company based in Vancouver, BC, Canada.

Filament Health is riding high with cash and cash equivalents of $4.6 million and working capital of $5 million as of the end of 2021. The Canadian company spent just $5.4 million on operating expenses last year.

Good news for 2022: Filament’s superpower was in leveraging its stock in 2021: issued 99,844 common shares to a service provider in exchange for the reduction of $39,938 in debts owing; issued 1,650,000 options to purchase common shares to six parties; and issued 226,000 restricted share unit awards, under which the holders have the right to receive an aggregate of 226,000 common shares.

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), is a biotechnology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction based in Vancouver, BC, Canada.

Mydecine appears to be regrouping after a discontinued operation cost them $5.3 million in 2021, which contributed to a net loss of $28.9 million for the year. For the two years ending December 2021, the company has experienced a combined net loss of just over $55.8 million. The Canadian company reports that it had $1.5 million in cash and cash equivalents as of the end of 2021, has secured additional funding and is moving forward with clinical trials and projects to expand its IP portfolio.

Good news for 2022: Mydecine progressed to a Phase 2b smoking cessation study following a positive meeting with the Food and Drug Administration (FDA) to review the company’s Investigational New Drug (IND) application. In Q2 2022, the company plans to file an IND and breakthrough status application and will begin patient recruitment upon receipt of FDA approval. The multi-site study’s lead investigator will be Johns Hopkins University. The company also signed a five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine, demonstrating the company’s commitment to advancing psychedelic medicine by exploring multiple molecules and drugs for various indications.


StaffMay 24, 2021
shutterstock_1789366847-1280x842.jpg

5min00

Patient-first biotech company Enveric Biosciences (NASDAQ: ENVB) is buying MagicMed Industries Inc., a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (DMT) and other molecular derivatives with applications across multiple indications, in an all-stock transaction. The deal has an approximate value of $30 million. 

Shareholders of MagicMed will receive 9,946,969 shares of common stock of Enveric, which recently closed at $2.72. Plus, warrants, options, and restricted stock units to acquire an additional 9,039,882 shares of common stock of Enveric. The current Enveric shareholders will own approximately 63.4% of the combined company’s common stock. Additionally, Enveric will receive approximately C$4 million in cash from the MagicMed Treasury. Dr. Joseph Tucker will be appointed Chief Executive Officer and David Johnson, the current Chief Executive Officer, and Chairman will be appointed Executive Chairman.

“Our proposed acquisition of MagicMed underscores the core fundamental mission of Enveric to form a drug discovery and clinical-stage biotechnology company with a focus on bringing forward nature-originated therapies to improve the standard of care and serve unmet needs in oncology and CNS indications,” said David Johnson, Chairman and CEO of Enveric Biosciences. “Psychedelics and cannabinoids, in our opinion, have extensive patient benefits for the mind and body. We welcome MagicMed’s world class research and development team led by Dr. Joseph Tucker, who not only have experience in psychedelic drug discovery, but also research experience in cannabinoids, as well.”

MagicMed has focused on the discovery and early development of novel drug candidates, structurally related to psychedelics with vastly improved pharmaceutical characteristics and commercial potential for the treatment of neurological and psychological indications. The Psybrary is MagicMed’s library of novel psychedelic derivatives developed through the combination of synthetic biology and traditional chemistry techniques. MagicMed has 13 patent applications filed for derivatives of psilocybin and DMT, 2 patent applications filed for derivatives of mescaline and MDMA with further intellectual property protection for mescaline, MDMA, ibogaine, and LSD in process. 

“Our mission at MagicMed has always been focused on unlocking the full potential of psychedelic-derived medicines for the treatment of neurological and psychological indications,” added Dr. Joseph Tucker, Chief Executive Officer of MagicMed. “Complementing our R&D capabilities, working together with Enveric will allow us to leverage the company’s clinical team, all of whom are focused on advancing our extensive pipeline of molecules through the clinic to help serve the millions of patients who are suffering from mental health issues around the globe. Through this acquisition – in the best interest of each of our respective teams – we have bolstered our pipeline, bringing together a seasoned team of experts with the leadership skills and knowledge that is crucial to creating a platform that aims to address large unmet total addressable markets.”

The acquisition of MagicMed will expand and complement Enveric’s current pipeline of naturally occurring compounds, which is primarily focused on cannabinoids, to now include a robust portfolio of psychedelic-derived molecules. Enveric intends to continue to develop patient-centric support care therapies in oncology and central nervous system (CNS) indications. Upon closing, Enveric intends to commence drug discovery and development for treatment of cancer-related Post Traumatic Stress Disorder (PTSD) patients who are currently in treatment for cancer and those who are in remission. It is anticipated that the PTSD drug development program holds the potential to be expanded in the future beyond cancer-related applications to include other patient populations, such as military veterans.


Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.